Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI

NCT00835848 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Myocardial Infarction

Interventions

DRUG: Exenatide
DRUG: Saline

Sponsor

Rigshospitalet, Denmark

Collaborators

[object Object]